OverviewSuggest Edit

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
TypePrivate
HQMilton, GB
Websiteimmunocore.com
Employee Ratings2.8

Locations

Immunocore is headquartered in
Milton, United Kingdom

Location Map

Latest Updates

Employees (est.) (Sept 2020)314
Revenue (FY, 2018)£24.3 M(+67%)
Cybersecurity ratingAMore

Key People/Management at Immunocore

Bahija Jallal

Bahija Jallal

Chief Executive Officer
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Show more

Immunocore Office Locations

Immunocore has offices in Milton, Conshohocken and Rockville
Milton, GB (HQ)
101 Park Dr
Conshohocken, US
181 Washington St #200
Rockville, US
2273 Research Blvd #220
Show all (3)

Immunocore Financials and Metrics

Summary Metrics

Immunocore's latest funding round in March 2020 was reported to be $170 m. In total, Immunocore has raised $490 m
Show all financial metrics

Immunocore Revenue

Immunocore's revenue was reported to be £24.28 m in FY, 2018
GBP

Revenue (FY, 2018)

24.3m

Gross profit (FY, 2018)

(59.3m)

Gross profit margin (FY, 2018), %

(244.3%)

Net income (FY, 2018)

(71.6m)

EBIT (FY, 2018)

(93.5m)

Cash (31-Dec-2018)

124.4m
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.0m6.4m14.3m17.3m14.6m24.3m

Revenue growth, %

212%

Cost of goods sold

83.6m

Gross profit

(59.3m)
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

7.2m3.4m5.0m3.8m2.3m16.3m50.9m219.7m134.4m82.9m124.4m

Accounts Receivable

1.1m1.2m2.0m1.6m307.3k203.0k186.0k1.0m258.0k4.4m

Inventories

Current Assets

7.2m4.5m6.1m5.8m3.9m18.0m54.3m228.7m191.2m143.5m171.2m
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.7m)(5.6m)16.8m(23.1m)(48.9m)

Cash From Operating Activities

11.3m40.3m(22.4m)(36.9m)(60.9m)(16.6m)

Cash From Investing Activities

58.0m

Cash From Financing Activities

3.0m404.0k197.7m96.0k19.1m101.0k
GBPFY, 2008

Financial Leverage

1 x
Show all financial metrics

Immunocore Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Immunocore Online and Social Media Presence

Embed Graph

Immunocore Frequently Asked Questions

  • Who are Immunocore key executives?

    Immunocore's key executives are Bahija Jallal and Bent Jakobsen.

  • How many employees does Immunocore have?

    Immunocore has 314 employees.

  • What is Immunocore revenue?

    Latest Immunocore annual revenue is £24.3 m.

  • What is Immunocore revenue per employee?

    Latest Immunocore revenue per employee is £77.3 k.

  • Who are Immunocore competitors?

    Competitors of Immunocore include LogicBio Therapeutics, F-star Biotechnology and KemPharm.

  • Where is Immunocore headquarters?

    Immunocore headquarters is located at 101 Park Dr, Milton.

  • Where are Immunocore offices?

    Immunocore has offices in Milton, Conshohocken and Rockville.

  • How many offices does Immunocore have?

    Immunocore has 3 offices.